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Abstract
Background
With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of
costs has been observed with medication costs replacing hospitalization and surgery as
major cost driver. We aimed to explore the evolution of IBD-related costs over two years of
follow-up.
Methods and Findings
In total 1,307 Crohn's disease (CD) patients and 915 ulcerative colitis (UC) patients were
prospectively followed for two years by three-monthly web-based questionnaires. Changes
of healthcare costs, productivity costs and out-of-pocket costs over time were assessed
using mixed model analysis. Multivariable logistic regression analysis was used to identify
costs drivers. In total 737 CD patients and 566 UC were included. Total costs were stable
over two years of follow-up, with annual total costs of €7,835 in CD and €3,600 in UC. How-
ever, within healthcare costs, the proportion of anti-TNF therapy-related costs increased
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from 64% to 72% in CD (p<0.01) and from 31% to 39% in UC (p < 0.01). In contrast, the pro-
portion of hospitalization costs decreased from 19% to 13% in CD (p<0.01), and 22% to
15% in UC (p < 0.01). Penetrating disease course predicted an increase of healthcare costs
(adjusted odds ratio (adj. OR) 1.95 (95% CI 1.02–3.37) in CD and age <40 years in UC (adj.
OR 4.72 (95% CI 1.61–13.86)).
Conclusions
BD-related costs remained stable over two years. However, the proportion of anti-TNF-
related healthcare costs increased, while hospitalization costs decreased. Factors associ-
ated with increased costs were penetrating disease course in CD and age <40 in UC.
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel
diseases (IBD), are characterized by chronic relapsing intestinal inflammation that may lead to
severe complications and disability. Therefore, IBD represent a high economic burden to soci-
ety.[1–8] The early onset and chronicity of IBD profoundly affects work productivity with
accompanying economic losses mainly resulting from sick leave and work disability accounting
for up to 50% of the total costs.[1;2;5–8]
With the introduction and increasing use of anti-TNF therapy in IBD, a major shift of costs
has been observed with medication costs replacing in-patient care, such as hospitalization and
surgery, as the greatest source of healthcare expenditure.[1] Most previous cost studies in IBD,
however, relied on a single measurement of costs and were performed before the introduction
of anti-TNF therapy in IBD.[2;3;7–10] Furthermore, only a limited number of studies have
aimed to identify factors predicting IBD-related costs.[1;4;10;11]
The ‘Costs Of Inflammatory bowel disease in the Netherlands’ or COIN-study has been ini-
tiated to generate longitudinal cost data in order to assess the impact of anti-TNF therapy on
IBD-related costs. In the present study we aimed 1) to assess the evolution of costs of IBD over
a period of two years, 2) to explore the contribution of healthcare, productivity and out-of-
pocket costs on IBD-related costs; and 3) to identify predictors for high costs over two years of
follow-up.
Material and Methods
Study design and patient population
From October 2010 to October 2011 we invited all IBD patients aged 18 years or older from
seven university hospitals and seven district hospitals to participate in the COIN-study by letter
(Fig 1).
A secure web-based questionnaire was developed to obtain baseline characteristics and col-
lect cost data on a three-month basis during two years of follow-up. The cohort organisation
and study follow-up protocol have been described in detail elsewhere.[1] The study was cen-
trally approved by the Ethics Committee of the University Medical Centre Utrecht.
Data collection
Demographic characteristics included gender, age, age at diagnosis, education level, work sta-
tus, family history, and smoking status. Clinical characteristics included subtype of IBD,
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disease duration and localization, disease behaviour, stoma or pouch surgery, and clinical dis-
ease activity.
In accordance with Drummond et al.[12], we distinguished three main IBD-related cost cat-
egories including healthcare costs, productivity losses and patient costs. Applying the human
capital approach, productivity losses were estimated by multiplying the self-reported number
of sick leave days from both paid and unpaid (i.e. voluntary work) work of patients and the
caregivers taking care of the sick persons by age- and sex-specific productivity losses. A work-
week was assumed to have at maximum of five working days. Patient costs were calculated
according to patient specifications. Reference prices used in the COIN-study are described in
S1 Table. All costs are expressed in 2011 euros, using Dutch consumer price index when appro-
priate. No discounting was applied, given the limited follow-up period of two years. Potential
predictive variables were identified from earlier studies on predictors for poor clinical outcome
or high healthcare-or productivity losses (S2 Table).
Statistical analysis
Data analysis was performed using SPSS version 18.0. Descriptive statistics were used to char-
acterize patients with CD and UC. We report means with a standard deviation (SD) and medi-
ans with an interquartile range (IQR). Comparisons between CD and UC patients were
analysed with Student’s t-test for continuous variables and χ2 for dichotomous variables. To
compare medians, the Mann-Whitney U test was used. Costs were reported as mean cost/
patient with a 95% confidence interval.
To control equality between the study population (i.e. responders) and the patients who
were lost to follow-up over time (i.e. non-responders) we performed a non-responder study.
To account for missing data and repeated measurements, we used a generalized mixed model
to compare costs between different subgroups.
Fig 1. Design of the COIN study.
doi:10.1371/journal.pone.0142481.g001
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We performed a multivariate logistic regression analysis to identify factors predicting
increase of healthcare costs over two-years of follow-up. As a dependent variable we used the
10 percent of patients who displayed the highest increase in healthcare costs over two years of
follow-up. Variables that reached borderline significance (p<0.1) in the univariate analysis
were considered for inclusion into the multivariate models. We fitted separate models for UC
and CD. P-values<0.05 were considered statistically significant.
Results
Study population
At baseline, 1,307 CD patients and 915 UC patients were included. The two-year follow-up
questionnaire was filled-out by 736 CD patients and 566 UC patients (response rates of 47%
and 54%, respectively). Additional response rates per time point are provided in S3 Table.
From the patients who were lost to follow-up, 10 subjects died during the follow-up period, 54
were unreachable due to automatic email response bouncing our request (possibly due to a
change of email address), 153 withdrew consent and 1,049 were lost for unknown reasons.
Responders were older (p<0.01) and had longer disease duration (p<0.01) as compared to
non-responders (S4 Table).
The baseline characteristics of the study population completing the two-year follow-up are
described in Table 1. CD patients were more often females (60% versus 46%, p<0.01), smokers
(19% versus 8%, p<0.01), and had a higher probability of previous abdominal surgery (56%
versus 19%) compared to UC patients. CD patients were more frequently treated with immu-
nomodulators (36% versus 23%, p<0.01) and/or anti-TNF (21% versus 4%, p<0.01) as com-
pared to UC patients.
IBD-related costs
Over the two-year follow-up period, IBD-related costs did not change (Fig 2A and 2B). The
mean annual IBD-related costs were €7,835 (95% CI €7,235- €9,563) for CD patients and
€3,600 (95% CI €2,865- €4,669) for UC patients. Healthcare costs accounted for the major part
of the IBD-related costs, 81% (€6,326 (95% CI €5,241- €7,102)) in CD and 65% (€2,340 (95%
CI €1,540- €3,105)) in UC. In addition, productivity losses accounted for 17% (€1,335 (95% CI
€860- €2,130)) of the total costs in CD patients and 31% (€1,120 (95% CI €571- €1,891)) in UC
patients, whereas out-of-pocket costs accounted for 2% (€174 (95% CI €95- €220) in CD and
4% (€140 (95%CI €110-€195) in UC. Associated healthcare costs per 3 months are displayed in
S5A and S5B Table.
In Fig 3A and 3B, the breakdown of healthcare costs over time in the CD and UC cohorts is
depicted. Although the absolute healthcare costs did not change significantly over the two
years of follow-up, the proportion of anti-TNF therapy-related costs increased from 64% to
72% in CD (p<0.01), and from 31% to 39% in UC (p<0.01). This was mainly due to an
increased use of anti-TNF over two years of follow up. This increase was accompanied by a
reduction of the proportion of hospitalization costs, which decreased from 19% to 13% in CD
(p<0.01), and from 22% to 15% in UC (p<0.01). The proportion of healthcare costs due to
surgery, outpatient clinic, other mediation use and diagnostic procedures remained stable over
time (S5C and S5D Table).
Predictors of healthcare costs
In Table 2 the results of the multivariate analysis on predictors of healthcare costs are shown.
In CD, penetrating disease course was associated with an increase of healthcare costs (adjusted
Costs of Inflammatory Bowel Diseases
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odds ratio (Adj. OR) 1.95 (95% CI 1.02–3.37)). Furthermore, anti-TNF therapy (Adj. OR 0.09
(95% CI 0.02–0.12)) and disease activity (0.47 (95% CI 0.24–0.93)) at three months of follow-
up were found to be associated with a decrease of healthcare costs over two years of follow-up.
This was mainly due to discontinuation of anti-TNF therapy in 20% of CD patients with dis-
ease activity. In case of UC, only age<40 years (n = 225, 39.8% of the UC population) was
found to independently predict an increase of healthcare costs (adj. OR 4.72 (95% CI 1.61–
13.86)). The percentage UC patients<40 years receiving Anti-TNF therapy increased from
4.9% at baseline to 9.9% over two years of follow up.
Discussion
The widespread use of anti-TNF in the treatment of patients with IBD has changed the health-
care landscape radically and has led to a major shift in cost profiles.[1] For the first time, we
prospectively show in a large longitudinal study that IBD-related costs remain stable over a
period of two years. In this period, we observed an ongoing shift of cost profiles with an
increasing proportion of anti-TNF-related healthcare costs and a reduction of hospitalization
costs.
Most of the IBD-related costs were incurred by anti-TNF therapy, both in CD and UC
patients. The present data underscore our previous observations that healthcare expenditures
in IBD shift from costs related to hospitalization and surgery to costs driven by medication use.
Table 1. Demographic and disease characteristics of the study population. SD: Standard deviation; IQR: Interquartile range; n/a: not applicable; NS:
not significant.
CD n = 737 UC n = 566 P-value
Male gender (%) 295 (4.0) 300 (53.0) <0.01
Age—years (± SD) 50.5 (13.5) 52.4 (12.9) 0.01
Smoking (%) <0.01
Current 137 (18.6) 45 (8.0)
Never 382 (51.8) 336 (59.4)
Ex-smoker 218 (29.6) 185 (32.7)
Low education (%) 445 (60.4) 314 (55.5) 0.08
Disease duration—median (IQR) 18.2 (10.1–18.2) 16.0 (9.0–16.0) <0.01
Disease localisation (%)
Large bowel 204 (27.7) 566 (100) n/a
Small bowel 152 (20.6)
Both small and large bowel 361 (49.0)
Unknown 20 (2.7)
Penetrating disease course (%) 400 (54.3) n/a
Clinical remission (%) 618 (83.9) 452 (79.9) 0.06
Abdominal surgery (%) 416 (56.4) 106 (18.7) <0.01
Medication use (%)
Mesalazine 175 (23.7) 373 (65.9) <0.01
Azathioprine 189 (25.6) 91 (16.1) <0.01
Mercaptopurine 51 (6.9) 36 (6.4) NS
Methotrexate 25 (3.4) 1 (0.2) NS
Prednisone 37 (4.9) 31 (5.5) NS
Budesonide 44 (6.0) 19 (3.4) NS
Inﬂiximab 72 (9.8) 14 (2.5) <0.01
Adalimumab 85 (11.5) 5 (0.9) <0.01
doi:10.1371/journal.pone.0142481.t001
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[1] Due to the differences in study design and study populations, it is difficult to compare our
results with other studies. For example, the recently published EPICOM cost data from a popu-
lation-based inception cohort of patients in the first year after the diagnosis reported that the
Fig 2. A. Three-monthly total costs per average CD-patient over two-year follow up.B. Three-monthly total costs per average UC-patient over two-year
follow up.
doi:10.1371/journal.pone.0142481.g002
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main cost drivers were investigative procedures (21%), surgical procedures (26%) and anti-
TNF therapy (15%).[13] Interestingly, 20% and 4% of their CD and UC patients were already
on anti-TNF therapy in the first year after diagnosis, which is almost identical to the rates
observed in our cohort (21% in CD and 3% in UC).
An important observation is the ongoing rise of anti-TNF therapy-related costs, with a con-
current reduction of hospitalization costs. A similar trend in increase of anti-TNF therapy-
related costs has been found in rheumatoid arthritis.[14;15] In two national registry cost-of-
Fig 3. A. The proportion of healthcare costs for an average CD-patient over two-year follow up.B. The proportion of healthcare costs for an average UC-
patient over two-year follow up.
doi:10.1371/journal.pone.0142481.g003
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illness studies covering 20-years of follow-up, a downward trend for all costs, apart from the
costs for anti-TNF, therapy has been reported. The decline of costs related to hospitalization in
IBD is consistent with the observed decrease in surgery and hospitalisation rates in population-
based studies.[16;17]
Even though healthcare cost differ to a large extend between Western countries, comparable
trends in treatment paradigms should have induced the same alterations in cost profiles as
observed in our study. For example, Kappelman et al. studied healthcare costs using medical
and pharmacy claims from an administrative database between 2003 and 2004, in which 10%
of all CD patients had at least two claims of infliximab infusions.[18] In this study, pharmaceu-
tical claims accounted for the largest proportion of healthcare costs (35%), from which inflixi-
mab was the most costly medication.
The large sample size and longitudinal data enabled us to study predictors of healthcare
costs over time. In CD, penetrating disease was found to be associated with an increase of costs
over two years of follow-up. This can be attributed to the fact that a penetrating disease is a pre-
dictor of poor outcome in CD, resulting in frequent surgery and hospitalizations[19–21]. Fur-
thermore, this complication of CD is often treated with anti-TNF compounds (26.9% in our
cohort, data not shown).
In UC patients younger than 40 years of age, an increase of healthcare costs was encoun-
tered as well. We found a 100% increase of anti-TNF use among young UC patients during two
years of follow-up. This finding is in line with previous studies in which younger age in UC
was found to be associated with a more severe disease course and an increased risk of relapses.
[22–24] Furthermore, young age is associated with more extended colitis in which escalating
therapy towards anti-TNF medication or surgery is frequently required.[25] In contrast, anti-
TNF therapy and disease activity were associated with a decrease of healthcare costs. This was
mainly due to the fact that in these patients, anti-TNF therapy was eventually discontinued.
Table 2. Multivariate logistic regression analyses of CD and UC patients with increase of healthcare costs as dependent variable.
CD UC
Variable Adj. OR (95% CI) p-value Adj. OR (95% CI) p-value
Age (at 3 months follow up)
< 40 years 1.03 (0.54–1.98) 0.93 4.72 (1.61–13.86) <0.01
>40 years (ref) 1 1
Disease duration (at 3 months follow up)
< 3 years 0.54 (0.17–1.68) 0.29 2.03 (0.55–7.54) 0.29
>3 years (ref) 1 1
Abdominal surgery in the past
Yes 0.68 (0.35–1.35) 0.27 3.36 (0.13–1.070) 0.07
No (ref) 1 1
Anti-TNF therapy (at 3 months follow up)
Yes 0.09 (0.02–0.12) <0.01 0.14 (0.02–1.40) 0.10
No (ref) 1 1
Disease activity (at 3 months follow up)
Yes 0.47 (0.24–0.93) 0.03 -
No (ref) 1
Penetrating disease course
Yes 1.95 (1.02–3.73) 0.04
No (ref) 1
doi:10.1371/journal.pone.0142481.t002
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Whether this was due to treatment failure, side effects or cessation of this drug because of treat-
ment success could not be discerned from our data.
Our study has several limitations. First, an inherent limitation of a longitudinal study using
a web-based questionnaire design is the high rate of loss to follow-up. We tried to reduce the
impact of this problem by using mixed models to correct for missing values. Furthermore, we
performed a non-responder study, which showed that responders (i.e. the individuals complet-
ing all questionnaires) were older and had a longer disease duration. Since costs in elderly IBD
patients are lower than in younger patients,[26] we may have underestimated total healthcare
costs. Interestingly, even in this relatively old population, the prescription of anti-TNF therapy
increased over a follow-up period of two years. Furthermore, we did not have clinical data such
as endoscopic or laboratory markers of disease activity at our disposal. Potentially, these might
prove to be important determinants of future healthcare costs as well. For example, deep ulcers
or high faecal calprotectin levels may predict a severe disease course with associated high costs.
In conclusion, there is an apparent shift in cost profiles from surgery and hospitalization
towards anti-TNF therapy. However, total IBD costs remain remarkably stable over time, sug-
gesting that the anti-TNF-related costs are compensated by a reduction of hospitalization
costs. This may corroborate the notion that investment in expensive medical therapy might be
cost-effective from a pharmaco-economical point of view,presuming that a reduction in hospi-
tal admission is equal with an improvement in quality-of-life. Whether long-term anti-TNF
therapy is truly cost-effective in IBD has yet to be determined. Further careful monitoring of
changes in the costs of care for IBD patients will aid timely, sensible economic decision-
making.
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